KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 119 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,566,163 | -11.6% | 1,915,047 | +18.1% | 0.00% | 0.0% |
| Q2 2023 | $2,901,624 | -49.2% | 1,621,019 | +10.3% | 0.00% | 0.0% |
| Q1 2023 | $5,714,982 | +59.1% | 1,469,147 | +39.0% | 0.00% | 0.0% |
| Q4 2022 | $3,592,552 | -51.4% | 1,056,633 | -22.0% | 0.00% | -50.0% |
| Q3 2022 | $7,399,000 | +13.4% | 1,355,176 | -6.3% | 0.00% | +100.0% |
| Q2 2022 | $6,523,000 | -1.5% | 1,446,402 | +60.9% | 0.00% | 0.0% |
| Q1 2022 | $6,625,000 | +0.2% | 898,906 | -12.6% | 0.00% | 0.0% |
| Q4 2021 | $6,615,000 | +15.3% | 1,028,882 | +4.4% | 0.00% | 0.0% |
| Q3 2021 | $5,735,000 | -44.7% | 985,382 | -2.0% | 0.00% | -50.0% |
| Q2 2021 | $10,379,000 | -18.6% | 1,005,721 | -17.0% | 0.00% | -33.3% |
| Q1 2021 | $12,750,000 | -21.9% | 1,211,971 | +14.9% | 0.00% | -25.0% |
| Q4 2020 | $16,328,000 | +29.3% | 1,054,762 | +22.0% | 0.00% | 0.0% |
| Q3 2020 | $12,624,000 | -66.7% | 864,678 | -56.8% | 0.00% | -66.7% |
| Q2 2020 | $37,881,000 | +105.6% | 2,000,078 | +108.5% | 0.01% | +100.0% |
| Q1 2020 | $18,427,000 | +72.9% | 959,251 | +72.5% | 0.01% | +100.0% |
| Q4 2019 | $10,660,000 | +92.3% | 556,056 | -3.5% | 0.00% | +50.0% |
| Q3 2019 | $5,542,000 | +458.1% | 576,123 | +247.6% | 0.00% | – |
| Q2 2019 | $993,000 | +4.0% | 165,763 | +1.3% | 0.00% | – |
| Q1 2019 | $955,000 | -36.7% | 163,566 | +1.6% | 0.00% | – |
| Q4 2018 | $1,508,000 | -68.3% | 160,921 | -42.3% | 0.00% | -100.0% |
| Q3 2018 | $4,750,000 | -45.0% | 278,877 | -45.1% | 0.00% | -50.0% |
| Q2 2018 | $8,631,000 | +476.6% | 507,986 | +355.4% | 0.00% | – |
| Q1 2018 | $1,497,000 | +99.6% | 111,545 | +42.8% | 0.00% | – |
| Q4 2017 | $750,000 | -15.4% | 78,107 | -3.3% | 0.00% | – |
| Q3 2017 | $887,000 | +108.2% | 80,747 | +71.7% | 0.00% | – |
| Q2 2017 | $426,000 | -58.4% | 47,033 | -41.0% | 0.00% | – |
| Q1 2017 | $1,024,000 | +7.1% | 79,724 | -21.6% | 0.00% | – |
| Q4 2016 | $956,000 | +102.5% | 101,702 | +109.6% | 0.00% | – |
| Q3 2016 | $472,000 | +70.4% | 48,514 | +17.6% | 0.00% | – |
| Q2 2016 | $277,000 | +188.5% | 41,264 | +284.0% | 0.00% | – |
| Q1 2016 | $96,000 | -97.9% | 10,747 | -97.6% | 0.00% | -100.0% |
| Q3 2015 | $4,642,000 | -8.2% | 440,808 | +137.1% | 0.00% | -66.7% |
| Q2 2015 | $5,059,000 | +8.3% | 185,882 | +21.9% | 0.00% | +200.0% |
| Q1 2015 | $4,670,000 | +185.5% | 152,541 | +249.0% | 0.00% | 0.0% |
| Q4 2014 | $1,636,000 | +389.8% | 43,704 | +357.4% | 0.00% | – |
| Q3 2014 | $334,000 | -31.6% | 9,555 | -8.8% | 0.00% | – |
| Q2 2014 | $488,000 | -26.4% | 10,481 | -51.1% | 0.00% | – |
| Q1 2014 | $663,000 | – | 21,455 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |